The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

Brief description of study

Atherosclerotic cardiovascular disease (ASCVD) is a disease of the arterial vessels that may result in a cardiovascular event such as heart attack, stroke, unstable angina, or a coronary revascularization. Clinical trials have shown that a class of drugs called proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), reduces such cardiovascular events in patients with ASCVD. This study is being done to learn more about the ability of PCSK9 inhibitors to reduce cardiovascular events in routine clinical practice (outside of a clinical trial) in patients with a recent cardiovascular event or revascularization procedure. This study is an observational study. It means that this study collects the information from a clinical/real-world setting.


Clinical Study Identifier: s20-00194
ClinicalTrials.gov Identifier: NCT04197453


If you are registered as a volunteer, please login to the dashboard to send referrals.